Goldman Sachs joins Ikonisys' series E:
This article was originally published in Clinica
Executive Summary
Ikonisys, a developer of cell-based diagnostic products, has secured $30m in a series E round. The financing came from existing shareholders in the New Haven, Connecticut firm and from new investor Goldman Sachs. The funds will enable Ikonisys to achieve further clinical milestones and launch new tests within its oncoFISH and fastFISH product lines. The oncoFISH portfolio focuses on cancer diagnostics, while the fastFISH line is dedicated to the prenatal detection of genetic disorders - both are designed to run on the Ikoniscope robotic digital microscopy platform. The company expects to launch the first two rare cell detection tests in 2008.